Home > Case Studies

Case Studies

---

• 36-year-old male with intermittent chest pain

• 38-year-old woman - a gastric bypass candidate

• 68-year-old woman in critical care

• 58-year-old woman with end-stage renal disease on transplant list

• 57-year-old male with worsening shortess of breath

• 67-year-old woman with history of heart failure

 

---

INDICATIONS

Activated DEFINITY^® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY^® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

This site is intended for U.S. Healthcare Professionals only.
DEFINITY, VIALMIX and INTELLIPIN are registered trademarks of Lantheus Medical Imaging, Inc.
Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.
© 2013 Lantheus Medical Imaging, Inc. All Rights Reserved.